InvestorsObserver
×
News Home

Seres Therapeutics Inc Up 10.98% To $4.55 After Earnings Miss

Wednesday, August 03, 2022 11:21 AM | InvestorsObserver Analysts

Mentioned in this article

Seres Therapeutics Inc Up 10.98% To $4.55 After Earnings Miss

Wednesday, August 3, 2022 - Seres Therapeutics Inc (MCRB) reported downside earnings and upside revenues.

Wall Street earnings per share (EPS) projections for Seres Therapeutics Inc were at a loss of $0.60 per share. The company missed those estimates with an EPS loss of $0.70 per share. The loss of $0.70 per share (which represents a -17% EPS surprise) led to the company's profits falling 32% compared to last year when the firm reported an EPS loss of $0.53 per share. The decline in Seres Therapeutics Inc's annual growth rate represents how the business isn't performing well amid current economic conditions.

Seres Therapeutics Inc reported Q2 2022 revenue of $1.2 million. The $1.2 million (0%) negative revenue surprise led to negative 77% growth year-over-year as the firm reported revenue of $5.3 million in its year-ago quarter. The higher earnings growth compared to revenue points to Seres Therapeutics Inc improving its profit margin.

The stock is up 10.98% to $4.55 after the report.

Despite Seres Therapeutics Inc reporting a decline in revenues, earnings increased signaling a rise in profit margins.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

InvestorsObserver gives the stock a Neutral Sentiment score at the moment based on recent trading.

Prior to the report, InvestorsObserver gave the stock an overall score of 57. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App